Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ raptor resources limited

Ann: ResApp Joins Startup Creasphere Digital Health Program, page-48

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 48 Last

Share
Profile

Follow
moneyinmouth

3,243 Posts.

674

04/10/19

10:16

Post #: 40721813
Share

Originally posted by AlCp: ↑

RAP is starting to gain traction like PCK, and unless PCK starts to sign big contract, it's MC is overvalue at $300M and I will investing for the big contract, whereas RAP's at 190M so it has more potential of increasing to PCK's value (with commercialisation interest and government grant announcements in the future), hence it's a safer bet for me right now.....and don't forget even with the 94M performance share, RAP's MC will be $800M compared to PCK's $1B with pps of $1 (and that's with RAP having the bigger revenue potential between them). That's how I current see it.

Expand

They're both undervalued.. Hence everyone knowing and talking about them..

I don't know why you would look at revenue when the actual intellectual property owned by the company should be the reason you're investing.

RAP Price at posting: 29.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Bitcoin: Current State of Play & Where to Next | Swyftx

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

There are more pages in this discussion • 430 more messages in this thread...

First 48 Last

Add RAP (ASX) to my watchlist